Highly rated in
Highly rated in
Check Dr. Amel Karaa's experience treating your condition:
About Dr. Amel Karaa

Amel Karaa is a Medical Genetics expert in Boston, Massachusetts. Karaa has been practicing medicine for over 20 years and is highly rated in 22 conditions, according to our data. Her top areas of expertise are MELAS Syndrome, Fabry Disease, Acid Sphingomyelinase Deficiency (ASMD), and Multiple Sulfatase Deficiency. She is licensed to treat patients in Massachusetts. Karaa is currently accepting new patients.

Her clinical research consists of co-authoring 49 peer reviewed articles and participating in 8 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Amel Karaa it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Amel Karaa accepts the following insurance:

  •  Ambetter
  •  Anthem

Call to see if your plan is accepted.
175 Cambridge St, Boston, MA 02114
Other Locations
55 Fruit St, Boston, MA 02114
102 Endicott St, Danvers, MA 01923
Background & Education
Graduate Institution
Other, 2003
Medical Genetics
Internal Medicine in MA
Hospital Affiliations
Massachusetts General Hospital
MassGeneral Hospital For Children
North Shore Medical Center - Salem Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)
View 6 Less Clinical Trials -

49 Total Publications

Case 10-2022: A 78-Year-Old Man with Marked Ventricular Wall Thickening.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors